Biotech Values

[DewDiligence]

HGSI: This can perhaps be construed as good news for investors insofar as NVS/HGSI presumably won’t waste any more money on the Albuferon program. Albuferon wasn’t going to be a commercial success in any case.

Although the BLA with the FDA is still pending, I’m taking the liberty of moving Albuferon from paragraph #2 to paragraph #6 (back-burner programs) in the next revision of “HCV: Most Likely to Succeed.”